Method for prevention and treatment of iron deficiency anemia of calves under conditions of arid zones

FIELD: veterinary medicine.

SUBSTANCE: method includes introduction of iron-dextrane preparation Sedimin-Se + IM on day 5-6 of life in a dose of 5 ml, and then immediate intramuscular injection of Hidropepton in a dose of 5 ml.

EFFECT: method provides prevention and treatment of iron-deficiency anaemia, improved antioxidant activity of blood serum of calves, decreased free radical oxidation under conditions of arid zones.

1 cl

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: method includes the introduction of deferoxaminum to mice. Deferoxaminum is introduced subcutaneously in a dose of 0.5 g/kg 2 times with a 3 day interval.

EFFECT: method makes it possible to simply and efficiently model iron deficiency anaemia in mice.

3 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to a compound of the structural formula (1), which possesses the activity increasing erythropoietin production. In formula

R1 represents a group of the structural formula

,

in which R4 and R5, each independently, represent a hydrogen atom, halogen atom or C1-C6alkyl group, R6 represents a hydrogen atom, halogen atom or C1-C6alkyl group, R7 represents a hydroxyC1-C6alkyl group, hydroxyhalogenC1-C6alkyl group, C1-C6alkoxyC1-C6alkyl group, which can have 1 substituent, independently selected from a group of substituents α, (C1-C6alkoxy)carbonyl group, C1-C6alkoxyC1-C6alkoxyC1-C6alkyl group, hydroxyC1-C6alkoxygroup, C1-C6alkylcarbamoyl group, (C1-C6alkyl)(C1-C6alkyl) carbamoyl group, (C1-C6alkyl)(C1-C6alkyl) carbamoylC1-C6alkyl group or C2-C7alkanoyloxyC1-C6alkyl group, α represents a hydroxygroup, Q1 ring represents a piperidinyl group, rings Q2 and Q3 represent a phenyl or pyridyl group, X represents a simple bond or methylene, R2 represents a C1-C3alkyl group and R3 represents a hydrogen atom.

EFFECT: invention relates to a pharmaceutical composition, containing the said compounds, to the application of a compound for obtaining a medication for the enhancement of erythropoietin production and to a method of treatment or prevention of a disease, caused by reduced erythropoietin production, such as anaemia.

33 cl, 1 tbl, 55 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to the field of pharmaceutics and deals with a pharmaceutical composition, which contains feline erythropoietin as an active ingredient, to which two or more polyethyleneglycol molecules with a non-branched chain are attached, with a water-soluble long-chain molecule having the molecular weight, constituting not less than 30 kDa and producing the haemopoietic effect. A haemopoietic medication and a medication for the treatment of anaemia are based on the said composition.

EFFECT: group of inventions provides the haemopoietic effect, which lasts for not less than seven days, when introduced to humans and/or animals.

8 cl, 4 dwg, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to haematology and enterology, and concerns treating anaemia in the patients with celiacia. That is ensured by an oral administration of iron bis-glycinate chelate in the form of an effervescent tablet, semi-solid or liquid dosage form in the range of doses of 5 to 200 mg a day that corresponds to 1 to 40 mg of an iron ion.

EFFECT: invention provides treating anaemia in the patients suffering celiacia by the effective absorption of orally administered iron bis-glycinate chelate.

11 cl, 3 tbl, 11 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary science and aims at treating and preventing alimentary anaemia in young pigs. A preparation contains an iron dextran complex, nanosized and zero-valent selenium (Se0), vitamin E, vitamin B12 and water in the following proportions, wt %: iron dextran complex 0.0001-80.0, selenium (Se0) 0.0001-5.0, vitamin E 0.0001-20.0, vitamin B12 0.0001-10.0, water for injections - the rest.

EFFECT: using the declared method provides compensating iron deficiency in young pigs, improving animal's growth and development, increasing total immunity and rapid adaptation to the varying ambient environment.

4 tbl, 4 ex, 4 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to a triazolopyridine compound of general formula [I] or a pharmaceutically acceptable salt, where the partial structural formula: is a group represented by any of the following formulae: or R1 is (1) a hydrogen atom, (2) C1-6alkyl group, (3) phenyl group or (4) C3-8cycloalkyl group; R2 is (1) a hydrogen atom, (2) C1-10alkyl group, (3) phenyl group, optionally substituted with identical or different 1-3 substitutes selected from the following groupB, (4) C3-8cycloalkyl group, (5) C3-8cycloalkenyl group, (6) thienyl group, optionally substituted with 1 substitute selected from halogen or C1-6alkyl group, (7) phenyl-C1-6alkyl group (wherein phenyl is optionally substituted with different or identical 1-2 substitutes selected from halogen, C3-8cycloalkyl or halogen-C1-6alkyl group) or (8) C3-8cycloalkyl-C1-6alkyl group; R3 is (1) a hydrogen atom, (2) a halogen atom, (3) C1-6alkyl group, (4) phenyl group (6) phenyl-C1-6alkyl group; and each of R4 and R5 are both hydrogen atoms or a group B: (a) a halogen atom, (b) C1-6alkyl group, (c) C3-8cycloalkyl group, (d) cyano group and (e) halogen-C1-6alkyl group. The invention also relates to the specific compounds, a pharmaceutical composition based on the compound of formula [I] and to use of the compound with the formula [I].

EFFECT: obtaining novel triazolopyrine compounds, having inhibitory activity on prolyl hydroxylase and capable of inducing erythropoietin production.

30 cl, 34 tbl

FIELD: veterinary medicine.

SUBSTANCE: method of normalisation of the thrombin time duration in newborn calves with iron deficiency anemia consists in the fact that ferroglukin 150 mg (2 ml) intramuscularly is prescribed to newborn calves with iron deficiency anemia, twice with the interval of 4 days, cresacyne 5 mg/kg per day, including it in the scheme of watering for 4 days, starting simultaneously with the first injection of ferroglukin and gamavit intramuscularly once a day in the morning of 0.05 ml/kg for 4 days, starting simultaneously with ferroglukin and cresacyne.

EFFECT: acceleration of normalisation of thrombin time duration, enables to reduce the risk of vascular complications in newborn calves with iron deficiency anemia, to revitalise the herd, to reduce mortality, to maintain the volume and quality of the meat and dairy products obtained from animals.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to clinical pharmacology and veterinary therapy. The method consists in administering the complex iron-dextran preparation Ferranimal-75M intramuscularly on the 5th day of calf's life in a dose of 3 ml in a combination with an intramuscular injection of the preparation Hydropeptone in a dose of 10 ml. Ferranimal-75M is injected 10 days later in a dose of 2 ml in a combination with an injection of Hyropeptone 5 ml intramuscularly in different points.

EFFECT: method provides higher antioxidative activity of calf's blood serum, reduced pro-oxidant action of iron and incorporated radionuclides, as well as higher iron accessibility in treating and preventing iron-deficiency anaemia in calves exposed to the chronic incorporated radiation.

FIELD: veterinary medicine.

SUBSTANCE: ferroglyukin is administered to new-born calves with iron deficiency anaemia at a dose of 150 mg (2 ml) intramuscularly, twice with an interval of 4 days. Crezacyne 5 mg/kg per day is included in the watering scheme for 4 days, starting simultaneously with the first injection of ferroglyukin. Gamavit is administered intramuscularly once a day in the morning at a dose of 0.05 ml/kg for 4 days, starting simultaneously with ferroglyukin and crezacyne.

EFFECT: method enables to normalise consistently the platelet activity in new-born calves with iron deficiency anaemia during a short period of exposure, transferring it to the level typical of healthy calves, after 4 days of treatment, and to provide long-term maintenance of platelet haemostasis in the optimal mode of operation, eliminating the risk of thrombotic complications in animals and contributing to their normal growth and development.

1 ex

FIELD: metallurgy.

SUBSTANCE: invention relates to casein succinylate of iron (III) wherein iron content varies from 4.5 wt % to 7 wt %, water solubility exceeds 92% while phosphorus-to-nitrogen ratio exceeds 5 wt %.

EFFECT: additionally, invention relates to production of iron (III) and to pharmaceutical composition containing casein succinylate of iron (III).

17 cl, 4 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: melanin having water-solubility of at least 80% and an paramagnetic centre concentration of at least 8·1017 spin/g is administered orally into the animals having been exposed to the radiation in a dose high enough to cause a spinal radiation injury; melanin is administered after dissolved in distilled water in the effective concentration. Melanin water is used as drinking water for the mice having been exposed to single and fractionated acute radiation, which is able to cause acute radiation disease. Melanin water is taken from the 1st to 30th day following the single radiation, or from the 1st day of the fractionated radiation to the 30th day on completion of the radiation.

EFFECT: higher survival rate, faster recovered haemopoiesis, body weight and orientation and motion activity.

7 tbl, 5 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises intramuscular administration of the tylosin-containing preparation at a dose of 0.05 ml/kg body weight once a day for 3-4 days in all forms of mastitis. The tylosin-containing preparation is used as the preparation of the following composition, wt %: colistin sulphate - 4.0-6.0; tylosin base - 4.0-6.0; benzyl alcohol - 4.0; water for injection - 15.0; 1,2-propylene glycol - 100.0%.

EFFECT: use of the claimed invention enables to improve the therapeutic efficacy of treatment of mastitis.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to clinical pharmacology and veterinary therapy. The method consists in administering the complex iron-dextran preparation Ferranimal-75M intramuscularly on the 5th day of calf's life in a dose of 3 ml in a combination with an intramuscular injection of the preparation Hydropeptone in a dose of 10 ml. Ferranimal-75M is injected 10 days later in a dose of 2 ml in a combination with an injection of Hyropeptone 5 ml intramuscularly in different points.

EFFECT: method provides higher antioxidative activity of calf's blood serum, reduced pro-oxidant action of iron and incorporated radionuclides, as well as higher iron accessibility in treating and preventing iron-deficiency anaemia in calves exposed to the chronic incorporated radiation.

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a group of inventions involving: using poractant alfa in a dose of 100 to 200 mg/kg in a combination with beclomethasone dipropionate in a dose of 0.6 to 0.8 mg/kg for preventing bronchopulmonary dysplasia (BPD) (versions) for producing a therapeutic agent for preventing BPD, a respective pharmaceutical composition and a kit for the same application.

EFFECT: reducing the levels of pulmonary oxidative stress markers, but is also combined with improving the external pulmonary mechanics: a synergetic reduction of MAP (mean airway pressure) has been shown.

14 cl, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of biochemistry, in particular to clostridial neurotoxins with a modified persistence. Claimed is a polypeptide, containing HC-domain, the first and, at least, one additional LC-domain with amino acid sequences, at least, 90% identical to the respective sequences of a neurotoxic component of botulotoxin of a serotype A, B, C1, D, E, F or G. Also claimed are nucleic acid, an expression vector and a host cell, intended for the expression of the said polypeptide. Also claimed are a method of obtaining and application of the said polypeptide, including as a component of a pharmaceutical composition, for treatment of a condition, associated with hyperactive cholinergic innervations of a muscle or a exocrine gland, and for cosmetic procedures, associated with wrinkles.

EFFECT: invention makes it possible to controllably vary a period of activity of clostridial neurotoxins.

12 cl, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: course of the complex exposure of audio-, video- and reflex therapy with an unconscious suggestion is carried out. That is preceded by administering epitalamine 10 mg dissolved in a physiological solution 5 ml by electrophoresis. Administration is binasal from a positive pole into a patient's nasal passages in a number of 10-15 procedures. The second electrode is placed on the occipital lobe or the cervicothoracic spine. The complex exposure involves watching video information, listening to audio musical information with an introduced suggestive relaxing fable repeated every 1 minute, and exposing through electrodes provided on the skin projections in biologically active points within the lesions to electrical current a spectral structure of which is formed by the same musical signal by an electric musical massager. That is combined with the electric stimulation of the reflex areas arranged in the lesions if feeling itching therein. The exposure length is 45-60 minutes, domiciliary in any time of the day, daily for 3-4 weeks.

EFFECT: effective exposure on the mechanisms eliminating or relieving the itching intensity by preparing the neuroregularoty structures of the patient's central nervous system by the following therapeutic stage of the two-staged integrated exposure according to the presented regimen.

3 ex

FIELD: medicine.

SUBSTANCE: what is performed is an endoscopic approach; further, biopsy forceps with a rolled complex bioplastic material cut in size of an ulcerous defect are introduced into a working path of a fibrogastroduodenoscope, laid on the ulcerous defect with the use of the biopsy forceps, and controlled with the use of an endoscopic examination 5-7 days later. The bioplastic material contains hyaluronic acid, a phosphate buffer system, omeprazole and clarithromycin taken in a certain equivalence ratio.

EFFECT: non-invasive treatment of ulcer and reduced length of mucosal tissue regeneration.

1 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: compounds can be applied for treatment of oncologic and autoimmune diseases. Invention also characterises method of obtaining conjugates, pharmaceutical composition and medication, which contains modified proteins. In general formulae 1 or 2 , R1 is selected from the group representing (CH3)2N-,

R2 is selected from the group representing where R3 as terminal substituent represents -NH2, or and R4 represents H or C1-C3alkyl.

EFFECT: novel compounds possess affinity for CD16a receptor.

18 cl, 20 dwg, 3 tbl, 19 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention discloses an immunogenic composition having an immunogenic activity on serogroup B and C Neisseria meningitidis containing (a) N. meningitidis serogroup C (NmC) oligosaccharide, (b) proteoliposome vesicles of the outer membrane of N.meningitidis (NmB) serogroup B and (c) NmB protein containing and an amino acid sequence presented in the description, or an immunogenic fragment of the above sequence, or a sequence min. 80% identical to the above sequence. The ingredient (a) may be conjugated with a carrier, e.g. with a protein, CRM197, a diphtherial anatoxin or a tetanus anatoxin. The immunogenic composition can contain aluminium hydroxide or MF59 as an adjuvant. What is described is a N.meningitidis serogroup B and C vaccine containing the described immunogenic composition.

EFFECT: using the invention enables preparing the combined vaccine eliciting an immune response on both serogroups of the agent.

6 cl, 4 dwg, 5 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biochemistry, particularly to recombinant fused protein dimers intended to inhibit or suppress immune response in a mammal, which bind human CD80 or human CD86 or the extracellular domain of any thereof, and has higher capacity for suppressing immune response than a dimer of the fused protein LEA29Y-Ig. Also disclosed are nucleic acids which code said dimers, expression vectors containing said nucleic acids, as well as recombinant host cells containing said nucleic acids and/or said vectors. Disclosed are pharmaceutical compositions for inhibiting or suppressing immune response in a mammal, which contain said fused protein dimers, as well as use of said dimers to produce drugs for inhibiting or suppressing immune response in a mammal, treating diseases or disorders of the immune system or treating organ or tissue transplant rejection in a mammal. Methods of producing said fused protein dimers are also disclosed.

EFFECT: invention provides effective inhibition or suppression of immune response in a mammal.

9 cl, 15 dwg, 11 tbl, 12 ex

FIELD: veterinary medicine.

SUBSTANCE: invention is a method of correction of immunobiochemical status of cows in the prenatal and postpartum periods. The invention comprises the following steps: the dry cows within 10-12 days prior to and 10-12 days after parturation are given orally the composite agent based on organic acids, containing fumaric, ascorbic, succinic and citric acid based on per dose, mg/kg body weight: fumaric acid - 3.0-5.0; ascorbic acid - 4.5-7.5; succinic acid - 6.0-10.0; citric acid - 1.5-2.5, in combination with dualfold intramuscular injection tetrahydrovit 30 days before and on the day of parturation at a dose of 10 ml/head, and threefold intramuscular injection of iron complex 30, 15 days before and on the day of parturation at a dose of 0.2 ml/10 kg bodyweight.

EFFECT: invention provides a correction of immunobiochemical homeostasis at the level providing for physiological parturation and the postpartum period and obtaining viable offspring.

14 tbl, 3 ex

Up!